UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

Nature medicine, 2021-11, Vol.27 (11), p.1954-1960

2021

Volltextzugriff (PDF)

Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial

Circulation (New York, N.Y.), 2021-04, Vol.143 (17), p.1673-1686

2021

Volltextzugriff (PDF)

Impact of Practice-Based Management of Pulmonary Artery Pressures in 2000 Patients Implanted With the CardioMEMS Sensor

Circulation (New York, N.Y.), 2017-04, Vol.135 (16), p.1509-1517

2017

Volltextzugriff (PDF)

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial

Circulation (New York, N.Y.), 2019-10, Vol.140 (18), p.1463-1476

2019

Volltextzugriff (PDF)

Effect of Cardiac Resynchronization Therapy on Myocardial Gene Expression in Patients with Nonischemic Dilated Cardiomyopathy

Journal of cardiac failure, 2007-05, Vol.13 (4), p.304-311

2007

Volltextzugriff (PDF)

Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US

JAMA cardiology, 2021-09, Vol.6 (9), p.1060

2021

Volltextzugriff (PDF)

Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials

Circulation. Heart failure, 2023-07, Vol.16 (7), p.e009837-e009837

2023

Volltextzugriff (PDF)

Interatrial Shunt Treatment for Heart Failure: The Randomized RELIEVE-HF Trial

Circulation (New York, N.Y.), 2024-09

2024

Volltextzugriff (PDF)

Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF

Circulation. Heart failure, 2023-11, Vol.16 (11), p.e010633

2023

Volltextzugriff (PDF)

Early Reduction in Ambulatory Pulmonary Artery Pressures After Initiation of Sacubitril/Valsartan

Circulation. Heart failure, 2021-07, Vol.14 (7), p.e008212-e008212

2021

Volltextzugriff (PDF)

Main Results Of The Empagliflozin Evaluation By Measuring Impact On Hemodynamics In Patients With Heart Failure Trial

Journal of cardiac failure, 2020-12, Vol.26 (12), p.1109-1110

2020

Volltextzugriff (PDF)

Association Between Change in Ambulatory Hemodynamic Pressures and Symptoms of Heart Failure

Circulation. Heart failure, 2021-11, Vol.14 (11), p.e008446-e008446

2021

Volltextzugriff (PDF)

Alterations in adrenergic receptor signaling in heart failure

Heart failure reviews, 2000-03, Vol.5 (1), p.7-16

2000

Volltextzugriff (PDF)

B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: Analysis from Breathing Not Properly (BNP) Multinational Study

Circulation (New York, N.Y.), 2002-07, Vol.106 (4), p.416-422

2002

Volltextzugriff (PDF)

Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients with Heart Failure with Reduced Ejection Fraction with and without Diabetes - The Define-HF Trial

Journal of cardiac failure, 2019-11, Vol.25 (11), p.937-938

2019

Volltextzugriff (PDF)

B-type natriuretic peptide and renal function in the diagnosis of heart failure: An analysis from the breathing not properly multinational study

American journal of kidney diseases, 2003-03, Vol.41 (3), p.571-579

2003

Volltextzugriff (PDF)

Peripherally inserted veno-venous ultrafiltration for rapid treatment of volume overloaded patients

Journal of cardiac failure, 2003-06, Vol.9 (3), p.227-231

2003

Volltextzugriff (PDF)

New developments in heart failure: Role of endothelin and the use of endothelin receptor antagonists

Journal of Cardiac Failure, 2000-12, Vol.6 (4), p.359-368

2000

Volltextzugriff (PDF)

017 - Pulmonary Artery Pressures Decrease Over Time during Heart Failure Management Guided by Ambulatory Hemodynamic Monitoring in Real World Setting

Journal of cardiac failure, 2016-08, Vol.22 (8), p.S8-S8

2016

Volltextzugriff (PDF)

Pulmonary Artery Pressures Decrease Over Time during Heart Failure Management Guided by Ambulatory Hemodynamic Monitoring in Real World Setting

Journal of cardiac failure, 2016-08, Vol.22 (8), p.S8-S8

2016

Volltextzugriff (PDF)

Uncovering Heart Failure in Patients with a History of Pulmonary Disease: Rationale for the Early Use of B‐type Natriuretic Peptide in the Emergency Department

Academic emergency medicine, 2003-03, Vol.10 (3), p.198-204

2003

Volltextzugriff (PDF)

B-Type Natriuretic Peptide Levels in Patients in the Emergency Department With Possible Heart Failure and Previous Stable Angina Pectoris and/or Healed Myocardial Infarction

The American journal of cardiology, 2005-11, Vol.96 (10), p.1370-1373

2005

Volltextzugriff (PDF)

Prevalence of Sleep Disordered Breathing in a Heart Failure Program

Congestive heart failure (Greenwich, Conn.), 2004-09, Vol.10 (5), p.217-220

2004

Volltextzugriff (PDF)

What causes elevated B-type natriuretic peptide in patients without heart failure?

Journal of the American College of Cardiology, 2003-03, Vol.41 (6), p.278-279

2003

Volltextzugriff (PDF)

What is in the differential diagnosis of a B-type natriuretic peptide level of 1,000 pg/ml?

Journal of the American College of Cardiology, 2003-03, Vol.41 (6), p.159-159

2003

Volltextzugriff (PDF)

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(31)

Sprache

Englisch
(31)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial

Impact of Practice-Based Management of Pulmonary Artery Pressures in 2000 Patients Implanted With the CardioMEMS Sensor

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial

Effect of Cardiac Resynchronization Therapy on Myocardial Gene Expression in Patients with Nonischemic Dilated Cardiomyopathy

Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US

Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials

Interatrial Shunt Treatment for Heart Failure: The Randomized RELIEVE-HF Trial

Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF

Early Reduction in Ambulatory Pulmonary Artery Pressures After Initiation of Sacubitril/Valsartan

Main Results Of The Empagliflozin Evaluation By Measuring Impact On Hemodynamics In Patients With Heart Failure Trial

Association Between Change in Ambulatory Hemodynamic Pressures and Symptoms of Heart Failure

Alterations in adrenergic receptor signaling in heart failure

B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: Analysis from Breathing Not Properly (BNP) Multinational Study

Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients with Heart Failure with Reduced Ejection Fraction with and without Diabetes - The Define-HF Trial

B-type natriuretic peptide and renal function in the diagnosis of heart failure: An analysis from the breathing not properly multinational study

Peripherally inserted veno-venous ultrafiltration for rapid treatment of volume overloaded patients

New developments in heart failure: Role of endothelin and the use of endothelin receptor antagonists

017 - Pulmonary Artery Pressures Decrease Over Time during Heart Failure Management Guided by Ambulatory Hemodynamic Monitoring in Real World Setting

Pulmonary Artery Pressures Decrease Over Time during Heart Failure Management Guided by Ambulatory Hemodynamic Monitoring in Real World Setting

Uncovering Heart Failure in Patients with a History of Pulmonary Disease: Rationale for the Early Use of B‐type Natriuretic Peptide in the Emergency Department

B-Type Natriuretic Peptide Levels in Patients in the Emergency Department With Possible Heart Failure and Previous Stable Angina Pectoris and/or Healed Myocardial Infarction

Prevalence of Sleep Disordered Breathing in a Heart Failure Program

What causes elevated B-type natriuretic peptide in patients without heart failure?

What is in the differential diagnosis of a B-type natriuretic peptide level of 1,000 pg/ml?

Suchergebnisse filtern